HK1146484A1 - Thiazolidinedione analogues for the treatment of hypertension - Google Patents

Thiazolidinedione analogues for the treatment of hypertension

Info

Publication number
HK1146484A1
HK1146484A1 HK11100608.1A HK11100608A HK1146484A1 HK 1146484 A1 HK1146484 A1 HK 1146484A1 HK 11100608 A HK11100608 A HK 11100608A HK 1146484 A1 HK1146484 A1 HK 1146484A1
Authority
HK
Hong Kong
Prior art keywords
hypertension
treatment
thiazolidinedione analogues
thiazolidinedione
analogues
Prior art date
Application number
HK11100608.1A
Other languages
English (en)
Inventor
Gerard R Colca
Robert C Gadwood
Tim Parker
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of HK1146484A1 publication Critical patent/HK1146484A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11100608.1A 2007-09-14 2011-01-21 Thiazolidinedione analogues for the treatment of hypertension HK1146484A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97263907P 2007-09-14 2007-09-14
PCT/US2008/010723 WO2009038681A1 (en) 2007-09-14 2008-09-15 Thiazolidinedione analogues for the treatment of hypertension

Publications (1)

Publication Number Publication Date
HK1146484A1 true HK1146484A1 (en) 2011-06-10

Family

ID=40239575

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100608.1A HK1146484A1 (en) 2007-09-14 2011-01-21 Thiazolidinedione analogues for the treatment of hypertension

Country Status (16)

Country Link
US (1) US8067450B2 (pl)
EP (1) EP2203433B1 (pl)
JP (1) JP5371988B2 (pl)
KR (1) KR101537830B1 (pl)
CN (1) CN101848901B (pl)
AU (1) AU2008301905B2 (pl)
BR (1) BRPI0817096B8 (pl)
CA (1) CA2699289C (pl)
ES (1) ES2398313T3 (pl)
HK (1) HK1146484A1 (pl)
IL (1) IL204440A (pl)
MX (1) MX2010002820A (pl)
NZ (2) NZ583889A (pl)
PL (1) PL2203433T3 (pl)
RU (1) RU2486179C2 (pl)
WO (1) WO2009038681A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007227581B2 (en) 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
CN101454006B (zh) 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
RU2486179C2 (ru) 2007-09-14 2013-06-27 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Аналоги тиазолидиндиона для лечения диабета и дислипидемии
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
CN102753539B (zh) * 2009-12-15 2015-09-09 新陈代谢解决方案开发公司 治疗代谢性疾病的ppar-节制的噻唑烷二酮盐
DK2512470T3 (en) * 2009-12-15 2017-02-27 Octeta Therapeutics Llc PPAR SAVING THIAZOLIDE INDIA AND COMBINATIONS TO TREAT NEURODEGENERATIVE DISEASES
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
MX2012006744A (es) * 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
WO2011084459A1 (en) * 2009-12-15 2011-07-14 Metabolic Solutions Development Company Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
HUE030263T2 (en) 2010-04-19 2017-04-28 Octeta Therapeutics Llc New synthesis for the preparation of thiazolidinedione compounds
KR20130064742A (ko) * 2010-04-21 2013-06-18 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 티아졸리딘디온 유사체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
PL2603507T3 (pl) * 2010-08-10 2016-12-30 Synteza związków tiazolidynodionu
EP2603498B1 (en) * 2010-08-10 2016-11-09 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
WO2012109495A1 (en) * 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
JP6498195B2 (ja) 2013-07-22 2019-04-10 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝疾患を処置するためのｐｐａｒ節約化合物
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
US20210038566A1 (en) 2018-02-08 2021-02-11 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1986002073A1 (en) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
ATE202352T1 (de) 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
WO2000066102A2 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
ES2437103T3 (es) 1999-06-30 2014-01-08 Amgen Inc. Compuestos para la modulacion de la actividad de PPAR gamma
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
EP1387843B1 (en) 2001-04-26 2007-02-28 Zentiva, a.s. Method for obtaining pioglitazone as an antidiabetic agent
WO2003026586A2 (en) 2001-09-28 2003-04-03 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
US7465801B2 (en) 2002-07-16 2008-12-16 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
US20060177444A1 (en) * 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
JP2005015477A (ja) * 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
WO2005021542A2 (en) 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
EP1797082B1 (en) 2004-09-28 2012-08-29 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
CN101454006B (zh) 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
AU2007227581B2 (en) 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
WO2007109088A2 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
RU2486179C2 (ru) 2007-09-14 2013-06-27 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Аналоги тиазолидиндиона для лечения диабета и дислипидемии
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues

Also Published As

Publication number Publication date
MX2010002820A (es) 2010-04-01
AU2008301905B2 (en) 2013-06-27
CA2699289C (en) 2016-01-19
US20100222399A1 (en) 2010-09-02
BRPI0817096A8 (pt) 2017-10-10
CA2699289A1 (en) 2009-03-26
AU2008301905A1 (en) 2009-03-26
ES2398313T3 (es) 2013-03-15
IL204440A (en) 2013-05-30
PL2203433T3 (pl) 2013-04-30
EP2203433B1 (en) 2012-10-31
WO2009038681A1 (en) 2009-03-26
US8067450B2 (en) 2011-11-29
JP2010539171A (ja) 2010-12-16
KR101537830B1 (ko) 2015-07-17
JP5371988B2 (ja) 2013-12-18
RU2010114727A (ru) 2011-10-20
CN101848901B (zh) 2012-11-21
NZ597381A (en) 2013-03-28
NZ583889A (en) 2012-01-12
CN101848901A (zh) 2010-09-29
BRPI0817096B1 (pt) 2020-11-10
BRPI0817096A2 (pt) 2017-05-02
EP2203433A1 (en) 2010-07-07
BRPI0817096B8 (pt) 2021-05-25
RU2486179C2 (ru) 2013-06-27
KR20100075915A (ko) 2010-07-05

Similar Documents

Publication Publication Date Title
HK1146484A1 (en) Thiazolidinedione analogues for the treatment of hypertension
HK1208237A1 (en) Methods for the treatment of gout
PL2001468T3 (pl) Analogi tiazolidynodionu
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
ZA200906129B (en) Compounds for the treatment of hepatitis c
ZA200806510B (en) Heterobicyclic sulfonamide derivatives for the treatment of diabetes
ZA200902374B (en) Compositions useful for the treatment of diabetes
HK1206262A1 (en) Implants for the treatment of dopamine associated states
SI2209784T1 (sl) Spojine za zdravljenje hepatitisa C
ZA201000923B (en) Compounds for the treatment of hepatitis c
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
GB0909297D0 (en) Composition for the treatment of skin conditions
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
ZA200807615B (en) Renin inhibitors for the treatment of hypertension
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
HK1129112A1 (en) 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders
GB0820885D0 (en) A composition for the treatment of hypertension
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602857D0 (en) The treatment of sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB2445888B (en) Treatment of hypertension
GB0705674D0 (en) Composition for the treatment of halitosis
PL1886669T3 (pl) Preparat o działaniu immunotropowym na bazie fosfoglukanu do leczenia przerostu migdałka gardłowego